These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 11910259)

  • 1. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study.
    Bergeron R; Ravindran AV; Chaput Y; Goldner E; Swinson R; van Ameringen MA; Austin C; Hadrava V
    J Clin Psychopharmacol; 2002 Apr; 22(2):148-54. PubMed ID: 11910259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.
    Ninan PT; Koran LM; Kiev A; Davidson JR; Rasmussen SA; Zajecka JM; Robinson DG; Crits-Christoph P; Mandel FS; Austin C
    J Clin Psychiatry; 2006 Jan; 67(1):15-22. PubMed ID: 16426083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.
    March JS; Biederman J; Wolkow R; Safferman A; Mardekian J; Cook EH; Cutler NR; Dominguez R; Ferguson J; Muller B; Riesenberg R; Rosenthal M; Sallee FR; Wagner KD; Steiner H
    JAMA; 1998 Nov; 280(20):1752-6. PubMed ID: 9842950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder.
    Kronig MH; Apter J; Asnis G; Bystritsky A; Curtis G; Ferguson J; Landbloom R; Munjack D; Riesenberg R; Robinson D; Roy-Byrne P; Phillips K; Du Pont IJ
    J Clin Psychopharmacol; 1999 Apr; 19(2):172-6. PubMed ID: 10211919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder.
    Cook EH; Wagner KD; March JS; Biederman J; Landau P; Wolkow R; Messig M
    J Am Acad Child Adolesc Psychiatry; 2001 Oct; 40(10):1175-81. PubMed ID: 11589530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial.
    Ghobadian A; Mokhtari S; Shariati B; Kamalzadeh L; Shati M; Eftekhar Ardebili M; Yarahmadi M; Shalbafan M
    BMC Pharmacol Toxicol; 2022 Sep; 23(1):73. PubMed ID: 36167636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder.
    Bisserbe J; Lane R; Flament M;
    Eur Psychiatry; 1997; 12(2):82-93. PubMed ID: 19698511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder.
    Wagner KD; Cook EH; Chung H; Messig M
    J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S53-60. PubMed ID: 12880500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
    Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
    BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
    Mowla A; Boostani S; Dastgheib SA
    J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.
    Chouinard G; Goodman W; Greist J; Jenike M; Rasmussen S; White K; Hackett E; Gaffney M; Bick PA
    Psychopharmacol Bull; 1990; 26(3):279-84. PubMed ID: 2274626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder.
    Zitterl W; Meszaros K; Hornik K; Twaroch T; Dossenbach M; Zitterl-Eglseer K; Zapotoczky HG
    Wien Klin Wochenschr; 1999 Jun; 111(11):439-42. PubMed ID: 10420495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients.
    Sechter D; Troy S; Paternetti S; Boyer P
    Eur Psychiatry; 1999 Mar; 14(1):41-8. PubMed ID: 10572324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insight and treatment outcome in obsessive-compulsive disorder.
    Eisen JL; Rasmussen SA; Phillips KA; Price LH; Davidson J; Lydiard RB; Ninan P; Piggott T
    Compr Psychiatry; 2001; 42(6):494-7. PubMed ID: 11704942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial.
    Liebowitz MR; Turner SM; Piacentini J; Beidel DC; Clarvit SR; Davies SO; Graae F; Jaffer M; Lin SH; Sallee FR; Schmidt AB; Simpson HB
    J Am Acad Child Adolesc Psychiatry; 2002 Dec; 41(12):1431-8. PubMed ID: 12447029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
    Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V
    J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
    Besiroglu L; Çetinkaya N; Selvi Y; Atli A
    Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
    J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 2-year study of sertraline in the treatment of obsessive-compulsive disorder.
    Rasmussen S; Hackett E; DuBoff E; Greist J; Halaris A; Koran LM; Liebowitz M; Lydiard RB; McElroy S; Mendels J; O'Connor K
    Int Clin Psychopharmacol; 1997 Nov; 12(6):309-16. PubMed ID: 9547132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.